(2022). Safety and Mortality: Monitoring the Patients on Rivaroxaban. test, 6(2), -. doi: 10.21608/cvrepj.2022.351489
. "Safety and Mortality: Monitoring the Patients on Rivaroxaban". test, 6, 2, 2022, -. doi: 10.21608/cvrepj.2022.351489
(2022). 'Safety and Mortality: Monitoring the Patients on Rivaroxaban', test, 6(2), pp. -. doi: 10.21608/cvrepj.2022.351489
Safety and Mortality: Monitoring the Patients on Rivaroxaban. test, 2022; 6(2): -. doi: 10.21608/cvrepj.2022.351489

Safety and Mortality: Monitoring the Patients on Rivaroxaban

Cardiovascular Research Prove Journal
Volume 6, Issue 2, December 2022    PDF (96.29 K)
Document Type: Abstracts
DOI: 10.21608/cvrepj.2022.351489
Abstract
No enough information available in matter of 
patient on Rivaroxaban a direct factor Xa 
inhibitor specially in Saudi population. In 
addition, patient with chronic kidney disease, 
valvular atrial fibrillation or liver disease must 
not be considered for such therapeutic change. 
Statistics
Article View: 33
PDF Download: 31